Results
fatigue, CFS, Fatigue
Of 11 patients, 10 were female. Patients’ mean age was 42.2 (± 6.7) years and the mean duration of CFS symptoms at randomization was 6.3 (± 2.5) years. After randomization into FMT or placebo, patients’ age or duration of CFS did not differ statistically significantly (Table Patient characteristicsThe average baseline VAS scores in the FMT and placebo groups were 62.4 (± 22.4) and 76.0 (± 3.6) (p = 0.29), respectively. Compared to the baseline scores, statistically significant changes at 1 or 6 months after the FMT/placebo were not found (Table VAS scores in the FMT and placebo groupsVisual Analogue Scale (VAS) scores (mean) (± SD) in the FMT and the placebo groups. 0 = no fatigue, 100 = extreme fatigue. The difference in baseline scores between the groups was statistically insignificant (p = 0.29)The MFIS scores are shown in the Table MFIS scores in the FMT and placebo groupsModified Fatigue Impact Scale (MFIS) scores (mean) (± SD) in the FMT and the placebo groups. Differences in the baseline scores between the groups were statistically insignificant (p values: Physical subscale 0.83; Cognitive subscale 0.99; Psychosocial subscale 0.27 and Total 0.80)The 15D-profiles in the FMT and placebo groups are shown in the Fig. 15D-scores in FMT and placebo groups. Severity levels in each dimension: 1 = no problems, 5 = extreme problems/unable. Compared to baseline scores, differences in 1 and 6 months scores are statistically non-significantTable EQ-5D-3L scores in the FMT and placebo groupsEQ-5D-3L profiles in individual patients. In each dimension, the first digit represents the severity of symptoms at baseline, the second and the third digits describe severity at 1 month and at 6 months after the FMT, respectively. 1 = no problems; 2 = some problems; 3 = extreme problems/unable. 1 month data of patient 3 missing